Nautilus Biotech makes progress with next-gen IFN-gamma - Pharmaceutical Business Review
‘French protein pharmaceuticals developer Nautilus Biotech has reported making progress on next-generation interferon gamma, having developed a set of novel molecules engineered to create an enhanced IFN-gamma.
If developed as a biopharmaceutical, this improved, highly stable version of IFN-gamma would allow less frequent injections of the drug.
The novel molecules, developed using Nautilus’ proprietary technology for protein improvement, are single mutants of IFN-gamma. They show significantly higher resistance to blood and intestinal proteases, while maintaining the native level of biological activity.
IFN-gamma is currently marketed for the treatment of chronic granulomatous disease and malignant osteopetrosis, and is in clinical trials for the treatment of idiopathic pulmonary fibrosis, certain forms of cancer and tuberculosis.’
Read more at Nautilus Biotech makes progress with next-gen IFN-gamma
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax